|Videos|January 22, 2021
ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas
Advertisement
A discussion on updates presented at the ASH (American Society of Hematology) 2020 Annual Meeting on developments in the management of relapsed/refractory B-cell lymphomas.
Data from the following clinical trials are discussed:
Abstract 339: Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial
Abstract 403: Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma
Abstract 2104: A Phase I Investigator Sponsored Trial of Selinexor (KPT-330) and Rituximab, Ifosfamide, Carboplatin and Etoposide in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas
Abstract 599: Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study
Abstract 598: Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis
Advertisement
Related to this article
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
A rituximab biosimilar has been approved by the FDA.
Shorter treatments of venetoclax plus azacitidine did not meet similarity criteria for longer treatments in the OPTI-AML trial.
The FDA has granted orphan drug designation to enzomenib for acute lymphoblastic leukemia.
FDA has granted RMAT and fast track designations to cema-cel as a frontline consolidation in large B-cell lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
Early mRNA Vaccine Data Excite Possibilities of Long-Term PDAC Remissions
2
FDA Flashback: GI Cancer Decisions and News From July 2026
3
TNFR2 Advances as a Novel Target for Restoring Antitumor Immunity Across Lymphoma and Solid Tumors
4
FDA Advisory Committee to Review Premarket Approval Application for Multi-Cancer Early Detection Test
5